NCT05359861 2026-03-18
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Completed
Clinical Trials
24 trialsNCT05665348 2026-03-09
TRIPLET
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT04862949 2025-12-12
Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
CHA University
Completed
NCT05908786 2025-12-11
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 1/2 Completed
NCT07272265 2025-12-09
The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study
Sun Yat-sen University
Phase NA Completed
NCT04487067 2025-09-22
AMETHISTA
Hoffmann-La Roche
Phase 3 Completed
NCT05197504 2025-09-05
HCC
CHA University
Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05750030 2025-05-06
FMT in IT-refractory HCC - FAB-HCC Pilot Study
Medical University of Vienna
Phase 2 Completed
NCT00410956 2024-12-10
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT06199297 2024-01-26
Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma
Sun Yat-sen University
Completed
NCT03434379 2023-10-23
IMbrave150
Hoffmann-La Roche
Phase 3 Completed
NCT01180959 2022-11-07
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00867321 2022-04-19
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT00335829 2021-08-13
Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Yale University
Phase 2 Completed
NCT00049322 2020-09-01
Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT01010126 2019-01-25
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00881751 2017-09-11
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Medical University of South Carolina
Phase 2 Completed
NCT00055692 2016-02-29
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00365391 2015-07-09
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00142467 2014-03-18
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT00467194 2013-06-17
Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
National Cancer Centre, Singapore
Phase 1 Completed
NCT00775073 2012-04-30
Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001
Treiber, Gerhard
Phase 2 Completed
NCT00287222 2011-07-15
Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
University of Arkansas
Phase 2 Completed